Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AbbVie receives EMA and FDA orphan drug designation for investigational compound ABT-414 in treatment of Glioblastoma Multiforme


Monday, 4 Aug 2014 08:00am EDT 

AbbVie Inc:Says the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to AbbVie's investigational compound ABT-414.ABT-414 is an anti-epidermal growth factor receptor antibody drug conjugate, which is being evaluated for safety and efficacy in patients with glioblastoma multiforme.1Glioblastoma multiforme is the most common and most aggressive type of malignant primary brain tumor. 

Company Quote

58.18
0.53 +0.92%
1:07pm EDT